299. 嚢胞性線維症
[臨床試験数:1,592,薬物数:1,539(DrugBank:255),標的遺伝子数:81,標的パスウェイ数:162]
Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02518672 (ClinicalTrials.gov) | October 2015 | 3/8/2015 | Pro-resolving Effect of MAG-DHA in Cystic Fibrosis (PREMDIC) | Role of DHA Monoglyceride (MAG-DHA) in the Resolution of Pulmonary Inflammation of Patients With Cystic Fibrosis. | Cystic Fibrosis | Dietary Supplement: MAG-DHA;Dietary Supplement: Placebo | SCF Pharma | Centre de recherche du Centre hospitalier universitaire de Sherbrooke;Solutex (Spain) | Terminated | 18 Years | N/A | All | 11 | Phase 2 | Canada |
2 | NCT02128984 (ClinicalTrials.gov) | January 2012 | 28/3/2014 | Clinical Study With an Enteral Formula With Symbiotic and DHA for Malnourished Children | Clinical Study With an Enteral Formula With Symbiotic and DHA for Malnourished Children | Cystic Fibrosis;Failure to Thrive;Malnutrition | Dietary Supplement: Symbiotic Formula with DHA and antioxidants;Dietary Supplement: Standard Formula | Laboratorios Ordesa | Quantum Experimental;Peruvian Clinical Research | Completed | 1 Year | N/A | All | 109 | N/A | Peru;Spain |
3 | EUCTR2010-020516-11-IT (EUCTR) | 16/09/2010 | 28/09/2010 | EXPERIMENTAL STUDY, RANDOMIZED, OPEN LABEL, TO EVALUATE THE EFFECT OF DOCOSAHEXAENOIC ACID (DHA) SUPPLEMENTATION VERSUS 5-METHYLTETHRAHYDROFOLATE + B12 VITAMIN AND DHA, IN CYSTIC FIBROSIS PATIENTS AND PANCREATIC INSUFFICIENCY - ND | EXPERIMENTAL STUDY, RANDOMIZED, OPEN LABEL, TO EVALUATE THE EFFECT OF DOCOSAHEXAENOIC ACID (DHA) SUPPLEMENTATION VERSUS 5-METHYLTETHRAHYDROFOLATE + B12 VITAMIN AND DHA, IN CYSTIC FIBROSIS PATIENTS AND PANCREATIC INSUFFICIENCY - ND | CYSTIC FIBROSIS AND PANCREATIC INSUFFICIENCY MedDRA version: 9.1;Level: PT;Classification code 10033628 MedDRA version: 9.1;Classification code 10011762 | Trade Name: PREFOLIC*30CPR GASTROR 15MG INN or Proposed INN: Detoxifying agents for antineoplastic treatment Trade Name: INDUSIL*OS GTT FL 30MG+FL 15ML INN or Proposed INN: Cobamamide | AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Italy | ||||
4 | NCT00221546 (ClinicalTrials.gov) | September 2007 | 12/9/2005 | Influence of DHA-rich Supplement on DHA-status and Health Evolution of Patients With Cystic Fibrosis | Influence of DHA-rich Supplement on DHA-status and Health Evolution of Patients With Cystic Fibrosis | Cystic Fibrosis | Drug: Giving DHA-rich supplement | University Hospital, Ghent | Belgian Society against Cystic Fibrosis | Completed | 6 Years | N/A | Both | 17 | Phase 2 | Belgium |
5 | NCT00530244 (ClinicalTrials.gov) | March 2003 | 13/9/2007 | Use of Formula Fortified With DHA in Infants With Cystic Fibrosis | The Effect of Formula Fortified With Docosahexaenoic Acid (DHA) on Infants With Cystic Fibrosis (CF) | Cystic Fibrosis | Dietary Supplement: Docosahexaenoic acid (DHA);Dietary Supplement: Standard formula (Enfamil) | University of Massachusetts, Worcester | Cystic Fibrosis Foundation | Completed | N/A | 56 Days | All | 76 | N/A | United States |